We are live on ! Find out more
OREX

Orexigen Therapeutics, Inc.
OREX

Delisted

OREX was delisted on the 3rd of April, 2018.

Back to rankings

129 hedge funds and large institutions have $605M invested in Orexigen Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 57 increasing their positions, 32 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 32

30% more capital invested

Capital invested by funds: $467M → $605M (+$138M)

29% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 21

20% more call options, than puts

Call options by funds: $12.2M | Put options by funds: $10.2M

4% more funds holding

Funds holding: 124 → 129 (+5)

Holders
129
Holders Change
+5
Holders Change %
+4.03%
% of All Funds
3.73%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
27
Increased
57
Reduced
32
Closed
21
Calls
$12.2M
Puts
$10.2M
Net Calls
+$2.04M
Net Calls Change
-$1.68M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$25.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$17.5M
3
Franklin Resources
Franklin Resources
California
+$11.5M
4
PAI
Palo Alto Investors
California
+$11.3M
5
FCMI
Foresite Capital Management I
California
+$8.45M

Top Sellers

Rank Fund Capital Flow
1
SCA
SAC Capital Advisors
Connecticut
-$22.5M
2
Capital Research Global Investors
Capital Research Global Investors
California
-$13.1M
3
AC
Apex Capital
California
-$5.63M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$5.59M
5
First Manhattan
First Manhattan
New York
-$5.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
CPIM
26
Columbia Partners Investment Management
Virginia
$5.56M +$5.78M +85,500 New
RSCM
27
Rock Springs Capital Management
Maryland
$5.39M +$2.06M +30,500 +58%
IGIM
28
I.G. Investment Management
Manitoba, Canada
$5.11M -$271K -4,000 -5%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$4.69M -$5.59M -82,709 -53%
TAM
30
Tiverton Asset Management
Delaware
$4.55M – – –
TA
31
Teachers Advisors
New York
$4.49M -$913K -13,499 -16%
SCA
32
SAC Capital Advisors
Connecticut
$4.4M -$22.5M -332,175 -83%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$3.78M +$595K +8,801 +18%
TCIM
34
TIAA CREF Investment Management
New York
$3.77M +$729K +10,776 +23%
OAM
35
Oxford Asset Management
United Kingdom
$3.63M +$3.78M +55,815 New
Geode Capital Management
36
Geode Capital Management
Massachusetts
$3.46M +$746K +11,032 +26%
Citigroup
37
Citigroup
New York
$3.44M -$125K -1,847 -3%
Principal Financial Group
38
Principal Financial Group
Iowa
$3.3M +$133K +1,960 +4%
Allianz Asset Management
39
Allianz Asset Management
Germany
$3.01M -$94.6K -1,399 -3%
EIM
40
Essex Investment Management
Massachusetts
$2.82M -$752K -11,112 -20%
GC
41
Guggenheim Capital
Illinois
$2.6M +$2.7M +39,921 New
DCM
42
Driehaus Capital Management
Illinois
$2.5M +$2.6M +38,428 New
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$2.38M +$332K +4,905 +13%
WA
44
Whitebox Advisors
Minnesota
$2.37M +$2.47M +36,499 New
JP Morgan Chase
45
JP Morgan Chase
New York
$2.22M +$331K +4,896 +17%
FM
46
Forward Management
California
$2.18M +$986K +14,571 +70%
RPAM
47
Rhenman & Partners Asset Management
Sweden
$2.14M +$536K +7,920 +32%
BIM
48
BlackRock Investment Management
Delaware
$2M +$205K +3,035 +11%
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$2M -$619K -9,146 -23%
PIM
50
Partner Investment Management
California
$1.98M +$437K +6,466 +27%
1
2
3 4 5

OREX Hedge Fund Activity: Q1 2014 in Review

129 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q1 2014, worth a combined $605M — up 30% from $467M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new OREX positions and 21 closed out — a net gain of 6 holders — while 57 added to existing stakes and 32 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $25.9M. The largest seller was SAC Capital Advisors, cutting an estimated $22.5M.

  • 129 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q1 2014, up from 124 in Q4 2013.
  • Funds reported $605M of Orexigen Therapeutics, Inc. stock for Q1 2014, up 30% quarter-over-quarter.
  • 27 funds opened new Orexigen Therapeutics, Inc. positions in Q1 2014 and 21 closed out, a net change of +6 holders.
  • The largest Orexigen Therapeutics, Inc. buyer in Q1 2014 was Fidelity Investments, an estimated $25.9M added.
  • The largest Orexigen Therapeutics, Inc. seller in Q1 2014 was SAC Capital Advisors, an estimated $22.5M sold.

Based on aggregated 13F filings for Q1 2014.